Compare Pfizer Inc (PFE) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Royal Caribbean Cruises Ltd — how do they compare? Pfizer Inc trades at $27.9 (market cap $158.39B), while Royal Caribbean Cruises Ltd trades at $261.61 (market cap $70.74B). The key difference: Pfizer Inc is far larger — about 2.2× Royal Caribbean Cruises Ltd's market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| PFE | RCL | |
|---|---|---|
Market Cap | $158.39B | $70.74B |
Volume | 29,869,932 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $350.23 |
52-Week Low | $23.60 | $246.71 |
Enterprise Value | $209.89B | $93.38B |
Dividend Yield | 6.19% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Royal Caribbean (RCL) trades at $264.5, down 0.26% on the day, with technical indicators showing a bearish trend near key support at $261. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $4.21 vs. $3.98, revenue growth to $17.93B in 2025, and robust profitability margins. Recent news highlights dividend declarations and institutional buying interest despite oil price concerns impacting cruise stocks.
The outlook remains positive with analyst consensus price target of $367.83 suggesting 39% upside, supported by earnings momentum and institutional accumulation. Key risks include oil price volatility affecting fuel costs and competitive pressures in the cruise industry. The stock presents a growth opportunity with solid fundamentals but requires monitoring of macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
